Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 451.139
Filtrar
1.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde, LIS-controlecancer | ID: lis-49654

RESUMO

O Atlas de Mortalidade por Câncer tem como uma de suas principais finalidades auxiliar os profissionais de saúde pública na determinação de prioridades necessárias à prevenção e ao controle do câncer.


Assuntos
Neoplasias , Mapas como Assunto , Mortalidade
2.
JAMA Netw Open ; 7(7): e2418639, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38949813

RESUMO

Importance: Serious illness conversations (SICs) that elicit patients' values, goals, and care preferences reduce anxiety and depression and improve quality of life, but occur infrequently for patients with cancer. Behavioral economic implementation strategies (nudges) directed at clinicians and/or patients may increase SIC completion. Objective: To test the independent and combined effects of clinician and patient nudges on SIC completion. Design, Setting, and Participants: A 2 × 2 factorial, cluster randomized trial was conducted from September 7, 2021, to March 11, 2022, at oncology clinics across 4 hospitals and 6 community sites within a large academic health system in Pennsylvania and New Jersey among 163 medical and gynecologic oncology clinicians and 4450 patients with cancer at high risk of mortality (≥10% risk of 180-day mortality). Interventions: Clinician clusters and patients were independently randomized to receive usual care vs nudges, resulting in 4 arms: (1) active control, operating for 2 years prior to trial start, consisting of clinician text message reminders to complete SICs for patients at high mortality risk; (2) clinician nudge only, consisting of active control plus weekly peer comparisons of clinician-level SIC completion rates; (3) patient nudge only, consisting of active control plus a preclinic electronic communication designed to prime patients for SICs; and (4) combined clinician and patient nudges. Main Outcomes and Measures: The primary outcome was a documented SIC in the electronic health record within 6 months of a participant's first clinic visit after randomization. Analysis was performed on an intent-to-treat basis at the patient level. Results: The study accrued 4450 patients (median age, 67 years [IQR, 59-75 years]; 2352 women [52.9%]) seen by 163 clinicians, randomized to active control (n = 1004), clinician nudge (n = 1179), patient nudge (n = 997), or combined nudges (n = 1270). Overall patient-level rates of 6-month SIC completion were 11.2% for the active control arm (112 of 1004), 11.5% for the clinician nudge arm (136 of 1179), 11.5% for the patient nudge arm (115 of 997), and 14.1% for the combined nudge arm (179 of 1270). Compared with active control, the combined nudges were associated with an increase in SIC rates (ratio of hazard ratios [rHR], 1.55 [95% CI, 1.00-2.40]; P = .049), whereas the clinician nudge (HR, 0.95 [95% CI, 0.64-1.41; P = .79) and patient nudge (HR, 0.99 [95% CI, 0.73-1.33]; P = .93) were not. Conclusions and Relevance: In this cluster randomized trial, nudges combining clinician peer comparisons with patient priming questionnaires were associated with a marginal increase in documented SICs compared with an active control. Combining clinician- and patient-directed nudges may help to promote SICs in routine cancer care. Trial Registration: ClinicalTrials.gov Identifier: NCT04867850.


Assuntos
Neoplasias , Relações Médico-Paciente , Humanos , Feminino , Masculino , Pessoa de Meia-Idade , Neoplasias/mortalidade , Neoplasias/psicologia , Neoplasias/terapia , Idoso , Comunicação , Adulto , Análise por Conglomerados , Pennsylvania
3.
Nat Commun ; 15(1): 5502, 2024 Jun 29.
Artigo em Inglês | MEDLINE | ID: mdl-38951519

RESUMO

Resistance to chemotherapy has been a major hurdle that limits therapeutic benefits for many types of cancer. Here we systematically identify genetic drivers underlying chemoresistance by performing 30 genome-scale CRISPR knockout screens for seven chemotherapeutic agents in multiple cancer cells. Chemoresistance genes vary between conditions primarily due to distinct genetic background and mechanism of action of drugs, manifesting heterogeneous and multiplexed routes towards chemoresistance. By focusing on oxaliplatin and irinotecan resistance in colorectal cancer, we unravel that evolutionarily distinct chemoresistance can share consensus vulnerabilities identified by 26 second-round CRISPR screens with druggable gene library. We further pinpoint PLK4 as a therapeutic target to overcome oxaliplatin resistance in various models via genetic ablation or pharmacological inhibition, highlighting a single-agent strategy to antagonize evolutionarily distinct chemoresistance. Our study not only provides resources and insights into the molecular basis of chemoresistance, but also proposes potential biomarkers and therapeutic strategies against such resistance.


Assuntos
Antineoplásicos , Sistemas CRISPR-Cas , Resistencia a Medicamentos Antineoplásicos , Irinotecano , Oxaliplatina , Proteínas Serina-Treonina Quinases , Resistencia a Medicamentos Antineoplásicos/genética , Humanos , Linhagem Celular Tumoral , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Oxaliplatina/farmacologia , Irinotecano/farmacologia , Sistemas CRISPR-Cas/genética , Proteínas Serina-Treonina Quinases/genética , Proteínas Serina-Treonina Quinases/metabolismo , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Neoplasias Colorretais/genética , Neoplasias Colorretais/tratamento farmacológico , Animais , Neoplasias/genética , Neoplasias/tratamento farmacológico , Repetições Palindrômicas Curtas Agrupadas e Regularmente Espaçadas/genética , Camundongos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
4.
BMC Cancer ; 24(1): 783, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38951760

RESUMO

BACKGROUND: The number of cancer survivors has increased in recent decades, and the majority of them suffer from sequelae of their disease and treatment. This study, which is part of the larger research project OPTILATER, aims to explore different aspects of care services for long-term survivors (≥ 5 years after initial cancer diagnosis) in Germany. The study places an emphasis on the situation of people from different age groups, with different socio-demographic and cultural backgrounds, and sexually and gender diverse individuals. METHODS: To investigate experiences related to follow-up care, focus groups (n = 2) will be conducted with members of patient advisory councils and advocacy groups, representatives of communities, healthcare workers and networks, as well as members of Associations of Statutory Health Insurance Physicians. Guided interviews will be carried out with patients and relatives (n = 40) to investigate needs, barriers and obstacles in terms of follow-up care. On this basis, additional focus groups (n = 2) will be carried out to derive possible scenarios for improving the consideration of needs. Focus groups and interviews will follow a semi-structured format and will be analysed content-analytically. Focus groups and interviews will be conducted online, recorded, transcribed, and analysed independently by two persons. DISCUSSION: The qualitative approach is considered suitable because of the exploratory research aims. The identification of experiences and barriers can reveal disparities and optimization potential in the care of long-term cancer survivors.


Assuntos
Sobreviventes de Câncer , Grupos Focais , Neoplasias , Pesquisa Qualitativa , Humanos , Sobreviventes de Câncer/psicologia , Feminino , Masculino , Neoplasias/terapia , Neoplasias/psicologia , Alemanha , Necessidades e Demandas de Serviços de Saúde , Pessoa de Meia-Idade , Adulto , Idoso
5.
Mol Cancer ; 23(1): 135, 2024 Jun 29.
Artigo em Inglês | MEDLINE | ID: mdl-38951876

RESUMO

In cells, signal transduction heavily relies on the intricate regulation of protein kinases, which provide the fundamental framework for modulating most signaling pathways. Dysregulation of kinase activity has been implicated in numerous pathological conditions, particularly in cancer. The druggable nature of most kinases positions them into a focal point during the process of drug development. However, a significant challenge persists, as the role and biological function of nearly one third of human kinases remains largely unknown.Within this diverse landscape, cyclin-dependent kinases (CDKs) emerge as an intriguing molecular subgroup. In human, this kinase family encompasses 21 members, involved in several key biological processes. Remarkably, 13 of these CDKs belong to the category of understudied kinases, and only 5 having undergone broad investigation to date. This knowledge gap underscores the pressing need to delve into the study of these kinases, starting with a comprehensive review of the less-explored ones.Here, we will focus on the PCTAIRE subfamily of CDKs, which includes CDK16, CDK17, and CDK18, arguably among the most understudied CDKs members. To contextualize PCTAIREs within the spectrum of human pathophysiology, we conducted an exhaustive review of the existing literature and examined available databases. This approach resulted in an articulate depiction of these PCTAIREs, encompassing their expression patterns, 3D configurations, mechanisms of activation, and potential functions in normal tissues and in cancer.We propose that this effort offers the possibility of identifying promising areas of future research that extend from basic research to potential clinical and therapeutic applications.


Assuntos
Quinases Ciclina-Dependentes , Humanos , Quinases Ciclina-Dependentes/metabolismo , Animais , Neoplasias/metabolismo , Neoplasias/patologia , Neoplasias/genética , Transdução de Sinais , Relação Estrutura-Atividade , Conformação Proteica
6.
Glob Health Res Policy ; 9(1): 24, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38951949

RESUMO

Gaps in access to quality essential medicines remain a major impediment to the effective care of children with cancer in low-and middle-income countries (LMICs). The World Health Organization reports that less than 30% of LMICs have consistent availability of childhood cancer medicines, compared to over 95% in high-income countries. Information provided within this policy brief is drawn from a review of the literature and a mixed-methods study published in the Lancet Oncology that analyzed determinants of cancer medicine access for children in Kenya, Tanzania, Uganda, and Rwanda. Three key policy options are presented to guide strategic policy direction and critical health system planning for strengthening access to cancer medicines for children: pooled procurement, evidence-based forecasting, and regional harmonization of regulatory processes. Enhancing regional pooled procurement to address fragmented markets and improve medicine supply, investing in health information systems for improved forecasting and planning of childhood cancer medicine needs, and promoting regulatory harmonization to streamline medicine approval and quality assurance across East Africa are recommended. This policy brief is intended for policymakers, clinicians, and health-system planners involved in the procurement, supply chain management, policy and financing of childhood cancer medicines.


Assuntos
Antineoplásicos , Política de Saúde , Acessibilidade aos Serviços de Saúde , Neoplasias , Humanos , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Criança , África Oriental , Neoplasias/tratamento farmacológico , Antineoplásicos/provisão & distribuição , Antineoplásicos/uso terapêutico , Previsões , Países em Desenvolvimento , Medicamentos Essenciais/provisão & distribuição
7.
Int J Nanomedicine ; 19: 6547-6575, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38957180

RESUMO

The development of therapeutic drugs and methods has been greatly facilitated by the emergence of tumor models. However, due to their inherent complexity, establishing a model that can fully replicate the tumor tissue situation remains extremely challenging. With the development of tissue engineering, the advancement of bioprinting technology has facilitated the upgrading of tumor models. This article focuses on the latest advancements in bioprinting, specifically highlighting the construction of 3D tumor models, and underscores the integration of these two technologies. Furthermore, it discusses the challenges and future directions of related techniques, while also emphasizing the effective recreation of the tumor microenvironment through the emergence of 3D tumor models that resemble in vitro organs, thereby accelerating the development of new anticancer therapies.


Assuntos
Bioimpressão , Neoplasias , Impressão Tridimensional , Engenharia Tecidual , Microambiente Tumoral , Humanos , Bioimpressão/métodos , Engenharia Tecidual/métodos , Microambiente Tumoral/efeitos dos fármacos , Neoplasias/terapia , Animais , Modelos Biológicos
8.
Annu Rev Biomed Eng ; 26(1): 273-306, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38959389

RESUMO

Nanomaterials are becoming important tools for vaccine development owing to their tunable and adaptable nature. Unique properties of nanomaterials afford opportunities to modulate trafficking through various tissues, complement or augment adjuvant activities, and specify antigen valency and display. This versatility has enabled recent work designing nanomaterial vaccines for a broad range of diseases, including cancer, inflammatory diseases, and various infectious diseases. Recent successes of nanoparticle vaccines during the coronavirus disease 2019 (COVID-19) pandemic have fueled enthusiasm further. In this review, the most recent developments in nanovaccines for infectious disease, cancer, inflammatory diseases, allergic diseases, and nanoadjuvants are summarized. Additionally, challenges and opportunities for clinical translation of this unique class of materials are discussed.


Assuntos
COVID-19 , Nanoestruturas , SARS-CoV-2 , Desenvolvimento de Vacinas , Humanos , Nanoestruturas/química , COVID-19/prevenção & controle , SARS-CoV-2/imunologia , Vacinas contra COVID-19/química , Animais , Adjuvantes Imunológicos/química , Neoplasias/imunologia , Neoplasias/prevenção & controle , Nanopartículas/química , Vacinas , Pandemias/prevenção & controle
9.
JCO Glob Oncol ; 10: e2400043, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38959449

RESUMO

PURPOSE: The study aims to explore unmet social needs and sources of financial toxicities in patients as noted by health care professionals and researchers in cancer supportive care, shedding light on potential health disparities. METHODS: In this cross-sectional survey, we anonymously surveyed active members of the Multinational Association of Supportive Care in Cancer (MASCC). The survey, structured in three sections, included questions regarding the routine assessment of social needs during patient consultations, sociodemographic aspects, factors influencing financial toxicity (FT), perceived support for managing FT, and available/desirable resources. RESULTS: A total of 218 MASCC members were included, predominantly from high-income countries (HIC, 73.4%), with many age 41-60 years (56.5%) and female (56.9%). Drug/treatment cost and insurance coverage were the main sources for FT among the HIC, whereas participants from low-middle-income countries (LMIC) considered transportation cost, loss of employment because of cancer diagnosis, and unavailability of return-to-work services as the top three sources of FT. Respondents from LMIC (adjusted odds ratio [aOR], 3.01 [95% CI, 1.15 to 7.93]) and physicians (aOR, 2.67 [95% CI, 1.15 to 6.21]) were more likely to routinely assess financial coverages. Socioeconomic status was consistently ranked as one of the top three sources of financial toxicities by participants from LMIC (34%), HIC excluding the United States (38%), those who do not self-identify as racial/ethnic minority (36%), and physicians (40%). CONCLUSION: This global survey of health care professionals and researchers in HIC and LMIC revealed varying approaches to assessing financial coverage and social needs. Socioeconomic status emerged as a consistent concern across countries, affecting financial toxicities. The study highlights the need for tailored approaches and improved resource visibility while emphasizing clinicians' pivotal role in addressing financial aspects of cancer care.


Assuntos
Neoplasias , Humanos , Neoplasias/economia , Neoplasias/terapia , Feminino , Estudos Transversais , Masculino , Pessoa de Meia-Idade , Adulto , Inquéritos e Questionários
10.
JCO Clin Cancer Inform ; 8: e2300245, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38959448

RESUMO

Primer that helps clarify large-scale clinical data sets and participant demographics for oncologists.


Assuntos
Neoplasias , Oncologistas , Humanos , Neoplasias/epidemiologia , Oncologia/métodos , Conjuntos de Dados como Assunto , Bases de Dados Factuais
12.
Adv Protein Chem Struct Biol ; 141: 123-176, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38960472

RESUMO

Metalloproteins represents more than one third of human proteome, with huge variation in physiological functions and pathological implications, depending on the metal/metals involved and tissue context. Their functions range from catalysis, bioenergetics, redox, to DNA repair, cell proliferation, signaling, transport of vital elements, and immunity. The human metalloproteomic studies revealed that many families of metalloproteins along with individual metalloproteins are dysregulated under several clinical conditions. Also, several sorts of interaction between redox- active or redox- inert metalloproteins are observed in health and disease. Metalloproteins profiling shows distinct alterations in neurodegenerative diseases, cancer, inflammation, infection, diabetes mellitus, among other diseases. This makes metalloproteins -either individually or as families- a promising target for several therapeutic approaches. Inhibitors and activators of metalloenzymes, metal chelators, along with artificial metalloproteins could be versatile in diagnosis and treatment of several diseases, in addition to other biomedical and industrial applications.


Assuntos
Metaloproteínas , Proteômica , Humanos , Metaloproteínas/metabolismo , Neoplasias/metabolismo , Doenças Neurodegenerativas/metabolismo , Doenças Neurodegenerativas/patologia
13.
Adv Protein Chem Struct Biol ; 141: 223-253, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38960475

RESUMO

Recent advances in genome-wide studies have revealed numerous epigenetic regulations brought about by genes involved in cellular metabolism. Isocitrate dehydrogenase (IDH), an essential enzyme, that converts isocitrate into -ketoglutarate (KG) predominantly in the tricarboxylic acid (TCA) cycle, has gained particular importance due to its cardinal role in the metabolic pathway in cells. IDH1, IDH2, and IDH3 are the three isomeric IDH enzymes that have been shown to regulate cellular metabolism. Of particular importance, IDH2 genes are associated with several cancers, including gliomas, oligodendroglioma, and astrocytomas. These mutations lead to the production of oncometabolite D-2-hydroxyglutarate (D-2-HG), which accumulates in cells promoting tumor growth. The enhanced levels of D-2-HG competitively inhibit α-KG dependent enzymes, inhibiting cell TCA cycle, upregulating the cell growth and survival relevant HIF-1α pathway, promoting DNA hypermethylation related epigenetic activity, all of which synergistically contribute to carcinogenesis. The present review discusses epigenetic mechanisms inIDH2 regulation in cells and further its clinical implications.


Assuntos
Epigênese Genética , Isocitrato Desidrogenase , Neoplasias , Isocitrato Desidrogenase/genética , Isocitrato Desidrogenase/metabolismo , Humanos , Neoplasias/genética , Neoplasias/metabolismo , Metilação de DNA
14.
Klin Onkol ; 38(3): 178-183, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38960673

RESUMO

BACKGROUND: Regardless of cancer type or stage of treatment, physical activity (PA) has been shown to reduce the risk of cancer recurrence and death. It is associated with a range of positive effects on patients' physical and psychological well-being, particularly in the areas of aerobic fitness, fatigue, mental health and perceived overall quality of life. However, in current oncology practice, the combination of its indication with treatment is still relatively rare. At the same time, cancer patients' participation in regular physical activity is usually very low. However, as PA is an effective method to support cancer treatment and plays an important role in prevention, it is necessary to find effective strategies to involve patients more widely in physical activities. To this end, physical activity programmes organised directly by facilities providing comprehensive cancer care appear to be very suitable. PURPOSE: This literature review maps the main barriers and facilitators to cancer patients' participation in physical activity programmes. In particular, economic factors related to health policy, reflected in the availability of this type of supportive care for patients, the level of health literacy, the organization of PA programs, health care providers - both physicians and health care workers, social support and intrapsychic influences on the part of patients play a major role. Since the implementation of physical activity programmes into the existing cancer care system is a rather challenging process, the paper also deals with the possibilities of using the Health Belief Model. In the given context, this model allows the prediction and identification of barriers and supportive factors to patients' involvement in PA programs in order to maximize their effectiveness and adapt them to the needs of patients and, at the same time, to the capabilities of a specific medical facility.


Assuntos
Exercício Físico , Neoplasias , Humanos , Neoplasias/psicologia , Neoplasias/terapia , Apoio Social , Qualidade de Vida
15.
Klin Onkol ; 38(3): 184-188, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38960674

RESUMO

BACKGROUND: Early diagnosis of cancer is essential for its effective treatment. Currently, established screening tests are cancer-specific and require screening for each type of cancer separately. The primary objective of cancer research is to develop methods that can detect multiple types of tumors from a single body fluid sample. Multicancer early detection tests aim to detect fragments of circulating tumor DNA, cell-free DNA, circulating microRNAs, or proteins released by cancer cells in the patient's body fluids. However, these tests are not suitable for routine cancer prevention due to their high cost. Therefore, in recent years, cancer screening tests have been developed to detect volatile organic compounds in urine using living organisms, such as nematodes, Caenorhabditis elegans. Measuring only 1 mm in length, C. elegans has the potential to offer a new, efficient, cost-effective, quick, and painless method to detect the presence of tumor. PURPOSE: The purpose of this review is to present an overview of the literature on the development and validation of C. elegans-based cancer detection methods. The potential benefits of these assays are significant, as they could become a valuable tool for the early identification and diagnosis of cancer, even though this research is still in its initial stages of development.


Assuntos
Caenorhabditis elegans , Detecção Precoce de Câncer , Neoplasias , Animais , Detecção Precoce de Câncer/métodos , Humanos , Neoplasias/diagnóstico , Biomarcadores Tumorais
16.
Psychooncology ; 33(7): e6373, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38946040

RESUMO

OBJECTIVE: The study aimed to evaluate the psychometric properties and measurement invariance (MI) of the Chinese version of the cognitive emotion regulation questionnaire-short (CERQ-short) in cancer patients. METHODS: This cross-sectional study included 505 cancer patients from mainland China. In addition to sociodemographic and clinical characteristics, the CERQ-short and the distress thermometer were included in the study measures. RESULTS: Item analysis indicated a promising result. And the results of CFA indicated that the CERQ-short demonstrated satisfactory factorial validity in cancer patients. Cronbach's alpha coefficients were between 0.663 and 0.910, while McDonald's omega coefficients were between 0.664 and 0.910. The CERQ-short had sufficient convergent, discriminant and concurrent validity among cancer patients. Lastly, MI supported that the CERQ-short demonstrated strong measurement equivalence across gender, residence and age. CONCLUSIONS: This study shows that the Chinese version of the CERQ-short has convincing psychometric properties and MI, which supports its use in cancer patients.


Assuntos
Regulação Emocional , Neoplasias , Psicometria , Humanos , Masculino , Feminino , Neoplasias/psicologia , Pessoa de Meia-Idade , Estudos Transversais , Inquéritos e Questionários/normas , China , Reprodutibilidade dos Testes , Adulto , Idoso , Cognição , Análise Fatorial
17.
Acta Oncol ; 63: 518-525, 2024 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-38946287

RESUMO

AIM: The study aims to investigate the impact of the COVID-19 pandemic on cancer patients' perceptions of the quality of their oncological treatment and care. BACKGROUND: The COVID-19 pandemic disrupted healthcare delivery and oncological resources were repurposed, potentially leading to prolonged treatment and reduced access to innovative therapies and clinical trials. Still, little is known about how patients perceived the quality of their treatment. METHODS: A cross-sectional study was conducted in the spring of 2020 among cancer patients at the Department of Oncology, Aarhus University Hospital and Rigshospitalet, Denmark. Patients were invited to complete an online questionnaire on clinical, socioeconomic, emotional, behavioural, and quality-related aspects of oncological cancer care. Patients who experienced reduced treatment quality and those who reported no or slight reductions were compared using multiple logistic regression, exploring the associations with patient characteristics, behaviours, and fear of cancer progression or recurrence. RESULTS: A total of 2,040/5,372 patients experienced changes in their treatment plans during the pandemic, and 1,570/5,372 patients experienced reduced treatment quality, with 236 reporting a high degree of reduction. Patients with breast, head and neck, and upper gastrointestinal cancers were more likely to experience reduced treatment quality. Altered interactions with healthcare providers, along with isolation, lack of social support, and heightened fear of cancer progression, were significant risk factors for experiencing reduced cancer care quality. INTERPRETATION: We identified subgroups of cancer patients needing targeted communication and care during health crises affecting cancer treatment. The findings underscore the importance of safeguarding the needs of vulnerable patient populations in future healthcare emergencies.


Assuntos
COVID-19 , Neoplasias , Medidas de Resultados Relatados pelo Paciente , Qualidade da Assistência à Saúde , Humanos , COVID-19/epidemiologia , Estudos Transversais , Feminino , Masculino , Neoplasias/terapia , Neoplasias/psicologia , Neoplasias/epidemiologia , Pessoa de Meia-Idade , Idoso , Dinamarca/epidemiologia , Qualidade da Assistência à Saúde/normas , Adulto , SARS-CoV-2 , Inquéritos e Questionários , Oncologia/normas , Pandemias
20.
Cancer Discov ; 14(7): 1145-1146, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38946323

RESUMO

Despite its long history of toxicity and limited efficacy, IL2 has re-entered the clinic as a companion to the recently FDA-approved tumor infiltrating lymphocyte therapy. In back-to-back articles, Moynihan and Kaptein introduce a new fusion protein that delivers a biased IL2 mutein to CD8 T cells. See related article by Moynihan et al., p. 1206 (6). See related article by Kaptein et al., p. 1226 (7).


Assuntos
Interleucina-2 , Neoplasias , Humanos , Interleucina-2/uso terapêutico , Neoplasias/tratamento farmacológico , Linfócitos T CD8-Positivos/imunologia , Linfócitos do Interstício Tumoral/imunologia , Linfócitos do Interstício Tumoral/efeitos dos fármacos , Linfócitos do Interstício Tumoral/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...